This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lam, K. S.-L. Articles by Tam, S. Search for Related Content PubMed PubMed Citation Articles by Lam, K. S.-L. Articles by Tam, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Serum Adiponectin Is Reduced in Acromegaly and Normalized after Correction of Growth Hormone Excess

Department of Medicine, University of Hong Kong (K.S.-L.L., A.X., K.C.-B.T., L.-C.W.); Department of Medicine, Queen Elizabeth Hospital (S.-C.T.); and Clinical Biochemistry Unit, Queen Mary Hospital (S.T.), Hong Kong

Address all correspondence and requests for reprints to: Dr. Karen Lam, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong. E-mail: ksllam{at}hkucc.hku.hk.

Adiponectin, an adipocyte-derived hormone, possesses insulin-sensitizing, antiinflammatory, and antiatherogenic properties. We hypothesized that hypoadiponectinemia was present in acromegaly, as in other conditions with increased insulin resistance and cardiovascular risk. Using an in-house RIA, serum adiponectin was determined in 35 patients with active acromegaly and 35 age-, sex-, and body mass index-matched healthy controls. Twenty-five patients were restudied after GH-lowering therapies. Serum adiponectin was significantly reduced in the acromegalic patients (4.3 ± 1.8 vs. 6.7 ± 1.8 µg/ml in controls; P < 0.001), but was increased after treatment with Sandostatin LAR, a long-acting somatostatin analog (5.8 ± 2.6 vs. 3.8 ± 1.6 µg/ml pretreatment; P < 0.001; n = 15) or transsphenoidal surgery (6.5 ± 2.7 vs. 3.9 ± 1.5 µg/ml preoperation; P < 0.01; n = 10). Fasting insulin was an independent determinant of serum adiponectin levels (P < 0.01) in control subjects, contributing to 11.7% of the variance in circulating adiponectin. In cultured 3T3-L1 adipocytes, adiponectin mRNA levels were decreased by insulin (1.5 µM; P < 0.005) or IGF-I (1 µg/ml; P < 0.05), but not by GH (1 µM) or somatostatin (1 µM). In conclusion, hypoadiponectinemia is present in active acromegaly, probably secondary to the inhibitory effect of high circulating insulin levels. Hypoadiponectinemia, reversible with GH-lowering therapies, may contribute to the increased insulin resistance and cardiovascular risk in patients with acromegaly.

This article has been cited by other articles:

				Z. Wang, M. M. Masternak, K. A. Al-Regaiey, and A. Bartke Adipocytokines and the Regulation of Lipid Metabolism in Growth Hormone Transgenic and Calorie-Restricted Mice Endocrinology, June 1, 2007; 148(6): 2845 - 2853. [Abstract] [Full Text] [PDF]

				H. Yamaza, T. Komatsu, K. To, H. Toyama, T. Chiba, Y. Higami, and I. Shimokawa Involvement of Insulin-Like Growth Factor-1 in the Effect of Caloric Restriction: Regulation of Plasma Adiponectin and Leptin J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2007; 62(1): 27 - 33. [Abstract] [Full Text] [PDF]

				R. H. Willemsen, M. van Dijk, Y. B. de Rijke, A. W. van Toorenenbergen, P. G. Mulder, and A. C. Hokken-Koelega Effect of Growth Hormone Therapy on Serum Adiponectin and Resistin Levels in Short, Small-for-Gestational-Age Children and Associations with Cardiovascular Risk Parameters J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 117 - 123. [Abstract] [Full Text] [PDF]

				M.-H. Gannage-Yared, S. Khalife, M. Semaan, F. Fares, S. Jambart, and G. Halaby Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur. J. Endocrinol., July 1, 2006; 155(1): 167 - 176. [Abstract] [Full Text] [PDF]